VSV-G pseudotyping allows HIV-2 entry in MDDCs. (a) HIV-2 binding. MDDCs were exposed to the indicated doses of HIV-2 GL-AN, pseudotyped or not with VSV-G. After 2 h at 4°C, cells were extensively washed and the amount of cell-associated p27 was assessed by ELISA. Data are Mean ± SD of 4 independent donors. ns: non significant (b) HIV-2 fusion. MDDCs were exposed to the indicated doses of HIV-2 GL-AN, pseudotyped or not with VSV-G, and bearing the chimeric protein β-lactamase-Vpr. After 2 h at 37°C, viral access to the cytoplasm was assessed by flow cytometry, using the ability of β -lactamase to cleave the cytoplasmic CCF2-AM fluorogenic substrate. One representative donor is shown in the upper panel and a mean ± SD of 3 independent donors in the lower panel. *: p-value < 0.05. Comparisons were made between the condition indicated and the no VSV condition at the same viral inoculum. (c) HIV-2 DNA synthesis. MDDCs were exposed to HIV-2 GL-AN, pseudotyped or not with VSV-G, in the presence or absence of AZT. After 3 days, the cells were harvested for HIV-2 DNA quantification by qPCR. Data are mean ± SD of 2 independent donors.